

1 **Elevated mucosal antibody responses against SARS-CoV-2 are**  
2 **correlated with lower viral load and faster decrease in systemic COVID-19 symptoms**

3  
4 Janeri Fröberg<sup>1,2\*</sup>, Joshua Gillard<sup>1,2,3\*</sup>, Ria Philipsen<sup>1,2,4</sup>, Kjerstin Lanke<sup>2</sup>, Joyce Rust<sup>1,2,4</sup>,  
5 Diana van Tuijl<sup>1,2,4</sup>, Teun Bousema<sup>2</sup>, Elles Simonetti<sup>1,2</sup>, Christa E. van der Gaast – de Jongh<sup>1,2</sup>,  
6 Mariska Bos<sup>1,2</sup>, Frank J. van Kuppeveld<sup>5</sup>, Berend-Jan Bosch<sup>5</sup>,  
7 Marringje Nabuurs- Franssen<sup>6</sup>, Nannet van der Geest-Blankert<sup>7</sup>, Charlotte van Daal<sup>7</sup>,  
8 Martijn A. Huynen<sup>3</sup>, Marien I. de Jonge<sup>1,2#</sup>, Dimitri A. Diavatopoulos<sup>1,2#</sup>

9  
10 **Affiliations:**

11 <sup>1</sup>Radboud university medical center, Radboud Institute for Molecular Life Sciences, Laboratory of  
12 Medical Immunology, Section Paediatric Infectious Diseases, Nijmegen, 6525 GA Nijmegen, The  
13 Netherlands, <sup>2</sup>Radboud Center for Infectious Diseases, Radboudumc, Nijmegen, <sup>3</sup>Centre for molecular  
14 and Biomolecular Informatics, Radboud Institute for Molecular Life Sciences, Radboud University  
15 Medical Centre Nijmegen, 6525 GA Nijmegen, The Netherlands, <sup>4</sup>RTC CS Radboud Technology  
16 Center Clinical Studies, Radboudumc, Nijmegen, <sup>5</sup>Utrecht University, Faculty of Veterinary  
17 Medicine, Department of Biomolecular Health Sciences, Division Infectious Diseases and  
18 Immunology, Utrecht, the Netherlands <sup>6</sup>Department of medical microbiology and infectious diseases,  
19 Canisius Wilhelmina hospital, Nijmegen, <sup>7</sup>Department of Occupational Health, Radboud university  
20 medical centre

21  
22 **Correspondence to:** Dr. Dimitri A. Diavatopoulos, Radboud university medical center, Radboud  
23 Institute for Molecular Life Sciences, Department of Laboratory Medicine, Nijmegen, 6525 GA  
24 Nijmegen, The Netherlands. Email correspondence to: dimitri.diavatopoulos@radboudumc.nl

25 \*, # contributed equally

26 **ABSTRACT**

27 Mucosal antibodies play a key role in protection against SARS-CoV-2 exposure, but their role during  
28 primary infection is not well understood. We assessed mucosal antibody responses during primary  
29 infection with SARS-CoV-2 and examined their relationship with viral load and clinical symptoms.  
30 Elevated mucosal IgM was associated with lower viral load. RBD and viral spike protein-specific  
31 mucosal antibodies were correlated with decreases in systemic symptoms, while older age was  
32 associated with an increase in respiratory symptoms. Up to 42% of household contacts developed  
33 SARS-CoV-2-specific mucosal antibodies, including children, indicating high transmission rates  
34 within households in which children might play an important role.

35 **INTRODUCTION**

36 Transmission within households is an important contributor to the spread of SARS-CoV-2, as close  
37 contact within households facilitates early-onset pre-symptomatic transmission of the virus.<sup>1-3</sup> The  
38 rapid spread of SARS-CoV-2 in populations is attributed to several aspects of the virus, i.e. route of  
39 transmission via respiratory droplets, rapid viral replication and shedding from the upper-respiratory  
40 tract<sup>4</sup>, early infectiousness with a peak viral load before onset of symptoms<sup>5,6</sup>, and a high frequency of  
41 mild and asymptomatic infections<sup>6-10</sup>. These aspects make controlling the outbreak difficult, as current  
42 control strategies are primarily dependent on symptomatic case detection<sup>11,12</sup>. Additionally, they  
43 indicate a high probability that pre-symptomatic carriers are important drivers of community-based  
44 transmission of the virus<sup>11,13</sup>. The role of children in transmission remains a highly debated subject, as  
45 children often develop asymptomatic or atypical disease which makes them prone to  
46 underdiagnosis<sup>3,9,14</sup>. A better understanding of the virology, immunology and clinical symptoms of  
47 mild SARS-CoV-2 infections in a community setting is therefore essential to track the spread of  
48 SARS-CoV-2 in the general population, and to inform intervention measures.

49  
50 Antibodies play a crucial role in the protection against viral re-infection by neutralizing the virus upon  
51 re-entry. SARS-CoV-2 enters human cells by binding to the ACE2 receptor with the receptor binding  
52 domain (RBD) of the Spike (S) protein. Serological studies have shown that antibodies directed  
53 against these antigens are capable of hindering SARS-CoV-2 infection, and vaccines targeting the S  
54 protein have been shown to be efficacious<sup>4,6,15,16</sup>. Infection with SARS-CoV-2 also induces humoral  
55 responses against the highly immunogenic nucleocapsid (N) protein. The N protein of SARS-CoV-2  
56 shares approximately 80% of its amino acid sequence with SARS-CoV-1 and other seasonal  
57 coronaviruses<sup>17</sup>. Therefore, pre-existing immunity against the N-protein may play a protective role  
58 during infection<sup>17,18</sup>. Studies investigating antibody response dynamics in mild cases have  
59 demonstrated the development of serum antibodies against SARS-CoV-2 approximately 10-15 days  
60 post symptom onset<sup>4,19</sup>. Relevance of serum antibodies to protection of severe disease is however  
61 equivocal, as some studies found that the antibody response in mild infections is transient<sup>20,21</sup>, while  
62 others reported robust and long-lasting antibody responses following mild infections<sup>22,23</sup>.

63  
64 An understudied aspect of the immune response to SARS-CoV-2 infection is the magnitude and  
65 kinetics of the mucosal antibody response. Studies of other coronaviruses conducted with controlled  
66 laboratory exposure have shown that mucosal antibodies play a key role in the reduction of viral load  
67 and may contribute to protection following re-exposure<sup>24,25</sup>. However, the vast majority of antibody  
68 studies on SARS-CoV-2 in humans thus far have focused on serum measurements, with relatively  
69 little attention to mucosal antibodies. To obtain a comprehensive view on the role of mucosal immune  
70 responses in mild SARS-CoV-2 infection, we performed a prospective, observational household  
71 contact study. We assessed the timing, magnitude and complexity of mucosal antibody responses

72 against SARS-CoV-2 antigens and examined their associations with viral load and COVID-19 related  
73 symptom development. Additionally, serological and mucosal antibody measurements were used to  
74 identify additional cases among close household contacts that were tested negative by PCR at study  
75 start. We observed the strongest increases in mucosal antibodies for IgM and IgG directed against S  
76 and RBD early after symptom onset, with elevated mucosal IgM levels associated with lower viral  
77 load. Increased RBD and S-specific mucosal antibodies correlated with decreases in systemic  
78 symptoms over the study period, while older age was associated with an increase in respiratory  
79 symptoms. Finally, we demonstrate that up to 42% of participating household contacts develop  
80 antibodies to SARS-CoV-2, including children, suggesting high transmission among household  
81 contacts. Child contacts were infected at a similar rate as adult contacts with similar viral load, but  
82 developed less symptoms compared to adults. Therefore the role of children in transmission might be  
83 underestimated.

84

## 85 RESULTS

### 86 Cohort description and study design

87 The recruitment strategy for inclusion of households focused on healthcare workers with a PCR-  
88 confirmed infection who were in home isolation (index cases) with at least two participating  
89 household members. Between 26 March 2020 and 15 April 2020, we enrolled 50 index cases and 137  
90 household members (**Figures 1a and b**). Home visits were planned to collect naso and oropharyngeal  
91 swab samples and nasal mucosal lining fluids (MLF) on the day of study enrolment (D0). In addition,  
92 MLFs were self-sampled on three subsequent timepoints and a serum sample was collected on the last  
93 day of the study. Index cases were asked to report their first day of symptoms, and all volunteers were  
94 asked to complete a daily symptom survey in order to monitor disease progression (**Figure 1c**). The  
95 analysis of mucosal antibody responses was compared with viral load, serological and symptom data.  
96 The general characteristics of study participants are shown in **Table S1**. Index cases were mostly  
97 female (76%) which is reflective of the gender amongst healthcare workers, with a median age of 46  
98 (IQR: 37-54), while household members were mostly male (61%) and younger, with a median age of  
99 21 (IQR:13-46). At inclusion, 46 (92%) of the index cases and 48 (35%) of the household members  
100 were PCR positive.

101

### 102 Serum antibody responses against SARS-CoV-2 in index cases and their household members

103 The magnitude of antibody responses was measured in serum and MLF using a fluorescent-bead-  
104 based multiplex immunoassay to quantify IgG, IgA and IgM isotypes specific for S- N- and RBD-  
105 antigens. We divided the log<sub>2</sub>-transformed antibody levels by the mean of control samples collected in  
106 the pre-SARS-CoV-2 period (n=32 for serum, and n=17 for MLF), to create a normalized value  
107 (relative ratio) that reflects the signal over background measurements.

108 Serum antibody responses, measured at the end of the study, were significantly higher in index cases  
109 than in controls for all antigens and isotypes (**Figure S1**). In order to evaluate differences between  
110 antibody isotype and antigen specificities, index cases were classified as seroconverted for each  
111 antigen and isotype, based on the difference between their sample and the negative control samples.  
112 By the end of the study, 96% of index cases and 53.28% of household members (contacts)  
113 seroconverted based on at least one antibody measurement, and the highest seroconversion rate was  
114 found for the S-protein (**Figure 2a**). Nearly all index cases (96%) seroconverted for S-protein IgG and  
115 IgA, while the seroconversion rate for RBD and N-protein was substantially lower or even absent (50  
116 and 70% for IgG and 2 and 0% for IgA, respectively). Similar patterns were found in the household  
117 contacts. In order to compare local (respiratory) versus systemic humoral immune responses, we  
118 correlated serum and MLF measurements taken at the end of the study. All correlations were positive  
119 and statistically significant, and were strongest for the IgM and IgG isotypes (**Figure 2b**), as has been  
120 previously reported for saliva and serum immunoglobulins<sup>26-28</sup>.

121

## 122 Mucosal antibody responses against SARS-CoV-2 in index cases

123 To examine the relationship between mucosal antibodies and virologic and clinical features, we  
124 focused on the index cases (n=50), as this group reported a date of symptom start. All index cases  
125 were included within two weeks of first experiencing symptoms (**Figure S2a**), and all data of the  
126 index cases were collected between 0 and 40 days post symptom onset (PSO) (**Figure S2b**), making  
127 the index cases a suitable cohort to examine these relationships during the acute phase of COVID-19  
128 disease. The viral load at study enrolment was non-significantly lower when the individual had a  
129 longer period of symptoms before study start (**Figure s3**). We correlated MLF antibody measurements  
130 collected at study start with viral load and the days since symptom onset. A higher mucosal IgA  
131 antibody level at enrolment was correlated with a longer period of symptoms before study start, while  
132 viral load was negatively correlated with IgM levels specific for RBD and S antigens (**Figure 3a**).  
133 This correlation pattern persisted after adjusting for age, sex, days since symptom onset for the viral  
134 load correlation, and viral load for the days since symptom onset correlation (data not shown).

135

136 To examine the kinetics of the mucosal antibody response, we measured the magnitude of antibody  
137 responses in the mucosal lining fluid of index cases at study day 0, 3, 6, and 28. Previous studies have  
138 shown that coronavirus-specific antibodies are significantly elevated in serum around two weeks PSO  
139 <sup>26,27,29</sup>. We examined longitudinal mucosal antibody responses by binning samples into three-day  
140 timeframes relative to the day of symptom onset and plotting the values alongside controls. Mucosal  
141 IgM, IgA, and IgG antibody levels for S and RBD antigens were significantly elevated relative to  
142 controls between 7-9 days PSO and remained high up to 40 days PSO, while for N protein only IgG  
143 antibody responses were significantly higher than controls after 28 days PSO (**Figure 3b**).

144 In order to study the temporal changes in the relationship between the antibody-antigen types, we  
145 calculated correlations among antibody responses within each timeframe. While IgA, IgG and IgM  
146 isotypes were highly intercorrelated between S and RBD near the start of symptom onset, at the final  
147 measurement (28+ days POS) correlations between the IgA-S and IgA-RBD isotype were much  
148 weaker. Correlations of N-protein antibodies with S and RBD were overall weaker until at least two  
149 weeks PSO, at which point the IgG-N response correlated with the IgG-RBD and IgG-S antibody  
150 measurements (**Figure 3c**).

151 Thus, SARS-CoV-2 infection induces a robust IgA, IgG, and IgM mucosal antibody response  
152 primarily against the S and RBD antigens as early as 7-9 days post symptom onset, while antibodies  
153 against N-protein show a different, slower induction and are overall restricted to IgG.

154

155

156 **Symptom progression in COVID-19 patients**

157 Mild COVID-19 disease is highly variable in its presentation and is generally characterized as a  
158 SARS-CoV-2 infection that does not require hospitalization or oxygen support and is not accompanied  
159 by severe symptoms like pneumonia<sup>4,8,30</sup>. We examined the progression of 23 symptoms using a  
160 survey that all volunteers filled in daily throughout the follow-up. To analyse the clinical  
161 manifestation of mild COVID-19 disease over a period soon after symptom onset, we focused on the  
162 index cases. The most frequently reported symptoms across the entire study period were fatigue,  
163 rhinorrhea, coughing, headache, and anosmia (**Figure S4a**). In order to compare different aspects of  
164 the clinical presentation, we grouped the symptoms into three categories: gastrointestinal symptoms  
165 (GS), systemic disease symptoms (SDS) and respiratory symptoms (RS). All index cases reported  
166 symptoms at the start of the study (**Figure S4b**). Fatigue was reported very frequently, and as such  
167 was not categorized (**Figure S4a and b**). We examined whether the symptom duration varied between  
168 different clinical presentations, and calculated the duration for each index case for each symptom  
169 group. The duration of SDS was significantly shorter than RS, and by the end of the study period  
170 nearly all index cases had resolved their SDS, while a quarter still reported RS (**Figure S4c**). To  
171 examine longitudinal changes in the magnitude of COVID-19 symptoms, we binned symptom  
172 notifications into three-day timeframes relative to the day of symptom onset, similar to the antibody  
173 analysis. While the number of SDS rapidly decreased from the time of symptom onset, RS appeared to  
174 stay high for at least two weeks post symptom onset (**Figure 4a**). We investigated if patient  
175 characteristics were associated with changes in symptoms over time. We constructed a linear mixed-  
176 effects model per symptom group with the number of reported symptoms as the response and time  
177 since symptom onset, age, and sex as covariates. Such a linear model was a good fit for our  
178 longitudinal symptom data (**Figure S5**). While time was significantly associated with decreases in  
179 symptoms, age was significantly associated with increased RS when correcting for the effect of time  
180 ( $p$ -value = 0.0165, **Figure 4b**). The sex had no effect on any symptom response group. To ascertain  
181 whether the induction of mucosal antibodies was associated with COVID-19 symptoms, the  
182 longitudinal mucosal antibody measures were added to the model in a univariate manner. This way,  
183 estimated changes in symptoms per unit increase of antibody signal represent the additional effect of  
184 antibodies while controlling for time, age, and sex. Increases in mucosal antibodies overall were  
185 associated with decreased SDS and RS. A significant association was only found for SDS, where high  
186 levels of IgM and IgG for S and all isotypes for RBD were related to a decrease in symptoms. The  
187 largest effect was seen in the relation between IgA-RBD and SDS (**Figure 4c**).

188

189

## 190 **SARS-CoV-2 infections in household contacts**

191 To examine infections amongst household clusters, we classified household contacts into cases or non-  
192 cases. Cases were classified first by their PCR result on enrolment, followed by seroconversion for  
193 one of the antibody isotypes against S-protein and mucosal antibody responses against S-protein at the  
194 end of the follow-up. The PCR positive threshold was set at a Ct value  $<36$ , corresponding to a viral  
195 load of  $\geq 10^3$  copies/ml. The seroconversion threshold was based on the mean +  $2*SD$  of the log<sub>2</sub>-  
196 transformed pre-SARS-CoV-2 control samples. To identify cases based on mucosal antibodies against  
197 S, we used a naive Bayes model that was trained by the mucosal antibody measurements of the PCR  
198 positive study participants (cases) and the pre-SARS-CoV-2 control samples (controls). Together, this  
199 approach identified 75 cases amongst 137 (54.7%) household contacts (**Figure 5a**), of whom 64%  
200 were PCR positive at study start, 87% were seropositive at the end of the follow-up, and 76% were  
201 identified as a case based on the MLF antibody levels at the end of follow-up (**table S2**). The majority  
202 of PCR positive cases also developed serum and MLF antibodies at the end of the study (88%). By  
203 including antibody measurements, 27 additional cases were identified (36% of cases).

204

205 All participants were asked if they were the first with COVID-19 related symptoms (primary case) in  
206 the household (parents were asked to answer for young children). This classification was solely based  
207 on symptoms, as only healthcare workers were eligible for PCR testing at the time of this study.

208 Among the contacts included in the study, nine were reported to be the primary case based on the  
209 timing of symptom onset. When we correlated their mucosal antibody responses to viral load, a similar  
210 negative correlation of IgM levels with viral load was observed for the S and RBD antigens as in the  
211 index cases (**Figure 5b**). We hypothesized that the primary cases within the household contacts would  
212 have been symptomatic for a longer period than the non-primary contacts. To see if this different stage  
213 of infection would be reflected in a difference in mucosal antibody levels, we plotted their mucosal  
214 antibody values in a similar manner as the index cases, using the day of symptom onset of the index  
215 case in the respective household as we did not have this data for the contacts. We found that primary  
216 cases, compared to secondary cases, had earlier and overall higher antibody responses for all antibody  
217 isotypes of S and RBD antigens (**Figure 5b**). Similar to the index cases, IgM and IgA antibody  
218 responses against the N-protein were relatively weak and were in range of the pre-SARS-CoV-2  
219 control samples.

220 The role of children in transmission of SARS-CoV-2 has been the subject of significant discussion.  
221 We therefore examined the likelihood that children  $<12y$  become infected. We found that 16 of the 33  
222 (48.5%) of the children  $<12y$  were infected, which was not significantly different compared to the  
223 59/104 (53.8%) in the  $>12y$  household contacts (p-value:0.78, **Figure 6a**). In the contacts above 50  
224 years, the proportion of infection was the highest (19/ 31, 61%). Most of these infected contacts above  
225 50 years were the partner of the index case (12/19, 63%), while all infected participants  $<12y$  were



226 children of the index case. Of note, 29% of all infected household members did not have any  
227 symptoms at study start, and 19% of all infected contacts remained asymptomatic throughout the  
228 entire follow-up. When examining the distribution of asymptomatic cases among the four age groups,  
229 we found that 7 out of the 16 (44%) cases <12y were asymptomatic at study start, compared to 11 of  
230 the 59 (20%) cases above 12y (p-value:0.10, **Figure 6b**). When we examined the overall number of  
231 symptoms that was reported throughout the follow-up, we noticed a strong and significant positive  
232 correlation between number of symptoms and age (**Figure 6c**). Despite the lower number of  
233 symptoms or absence of symptoms in child cases, no differences were found in viral load compared to  
234 the older age categories, nor were the serum antibody levels at the end of the follow-up different  
235 between the age-groups (**Figure s6a and b**).

236

237

238

239 **DISCUSSION**

240 In this study, we examined the mucosal antibody responses following infection with SARS-CoV-2 and  
241 the development of mild COVID-19 disease in 50 adults and their household contacts. This study  
242 demonstrates the unique value of using mucosal lining fluid to assess various aspects of SARS-CoV-2  
243 infection, ranging from pathophysiology to epidemiology.

244

245 Overall, we observed a significant increase in antibody levels measured in the mucosal lining fluid of  
246 the index cases, with a timing that is similar to what has previously been described for serum and  
247 saliva<sup>6,26,27</sup>. Mucosal IgG and IgM antibody responses measured against the three viral antigens  
248 correlated strongly with serum antibody levels, but were weaker for IgA, measured at 28-40 days PSO.  
249 This has previously been described for saliva<sup>26,27,31</sup>. A key finding of this study is that the mucosal IgA  
250 response against RBD showed the strongest relation to resolution of systemic disease symptoms. This  
251 phenomenon has also been addressed by Butler *et al.*<sup>32</sup> in a smaller cohort (n=20). They found that  
252 strong mucosal IgA responses against SARS-CoV-2 was related to neutralizing activity and that  
253 elevated levels of mucosal neutralization were associated with mild and moderate symptoms. This  
254 neutralizing activity of IgA has also been described in a bigger study that mainly focused on serum<sup>33</sup>.  
255 Another study in one family showed spiking salivary IgA levels at the time of symptom resolution,  
256 while serum antibody levels remained low.<sup>3</sup> Our larger study, including for the first time the dynamic  
257 measurement of the lining fluid of the upper respiratory tract, clearly shows the relation of mucosal  
258 antibodies with a decrease in symptom burden. Nevertheless, we did not measure neutralizing activity,  
259 and found that other mucosal responses against S and RBD also contributed to a reduction of systemic  
260 disease symptoms. Another significant finding was the negative correlation between viral load and  
261 mucosal IgM against RBD and S, measured at study start, suggestive of a neutralizing role of mucosal  
262 IgM, although other possible explanations, like pre-existing T-cell immunity cannot be excluded<sup>34,35</sup>.

263

264 Thus, a strong mucosal antibody response might play an important role in preventing severe disease,  
265 by reducing the systemic symptoms and reducing viral load. Patients with severe COVID-19 are  
266 sometimes treated with convalescent plasma from patients who have recovered from COVID-19<sup>36,37</sup>.  
267 Given their multimeric nature, IgM and IgA antibodies specific for RBD are likely to neutralize  
268 SARS-CoV-2 particles and strong neutralizing capacity has been described previously for both  
269 isotypes<sup>33,38</sup>. Therefore we propose that these antibodies should be included in the quality evaluation of  
270 convalescent plasma. Moreover, monitoring of SARS-CoV-2-specific antibody concentration in MLF  
271 in patients receiving convalescent plasma may yield important insights into which doses are required  
272 to reach sufficient concentrations at the primary site of infection. Intranasal administration of SARS-  
273 CoV-2 specific IgM or IgA in patients recently diagnosed with COVID-19 may provide an additional  
274 treatment option.

275 Because we measured the mucosal response of three antibodies against three different antigens, we  
276 were able to describe correlations between these antigen/isotype combinations. We found that there  
277 was a coherent antibody production against S and RBD early in the infection. Correlations between S  
278 and RBD with the N antigen were significantly less pronounced, and only emerged later in the  
279 infection, mostly for IgG. This indicates that the antibody response to the nucleocapsid antigen follows  
280 a different track after infection, than S and RBD, which was also seen in previous studies<sup>26,27,31</sup>. This  
281 variation in the antibody response composition could be explained by the cross-reactivity with other  
282 seasonal coronaviruses. Previous exposure with these coronaviruses could elicit a booster response  
283 instead of a primary immune response during SARS-CoV-2 exposure, explaining the presence of IgG  
284 and IgA and absence of IgM, which has the strongest response after primary exposure. Next to this,  
285 the release of N-proteins requires the lysis of virally infected cells, as it encapsulates the viral RNA.  
286 This could explain the difference in timing and the generally low mucosal antibody responses against  
287 N, as all our participants developed mild disease.

288

289 The ability to measure the mucosal antibody response over a longer period of time in an easy, non-  
290 invasive manner allowed us to identify cases among the household members that were not picked up  
291 by PCR-testing at a single timepoint only. When we performed the study, we were unable to collect  
292 additional samples for viral PCR due to shortages in swabs and transport medium, limiting our ability  
293 to fully study the dynamic interactions between viral infection and antibody responses, and calculate  
294 the sensitivity of the antibody measurements in diagnosing infection in comparison to PCR.

295 We observed a very high proportion of cases among the household contacts (54.7%), which is much  
296 higher than previously reported (11-37%)<sup>39-41</sup>. This can partly be explained by the fact that not all the  
297 index cases were the primary case, due to the restricted PCR testing on specific risk-groups at the time  
298 the study was performed. By using the households' primary case reporting, the secondary attack rate  
299 (SAR) was lowered to 49.6%. The fact that we still find a higher SAR than described in previous  
300 studies may be explained by the fact that almost all household transmission studies to date identified  
301 cases based on PCR positivity only, and thus underestimate the true number of cases within a cluster.  
302 PCR testing is prone to false negative results due to it being a one-time measurement, its dependency  
303 on the time of sampling in relation to the infection, and the chance of errors during sample collection.  
304 By combining PCR, serology and mucosal data, we were able to identify an additional 27 cases,  
305 increasing the total number of contact cases by a third. Although we used the mucosal antibody levels  
306 as an exploratory case-identification tool and used PCR and serology for most of the case  
307 identifications, the majority of serum and PCR positive contacts also had mounted a mucosal antibody  
308 response towards the end of the follow-up (**Table S2**). These results suggest that mucosal lining fluid  
309 could be used as a non-invasive way to measure disease exposure in a community setting, and as a tool  
310 to identify the primary case in a household.

311

312 Children were initially thought to play less of a role in SARS-CoV-2 infection and transmission,  
313 because of a lower expression of ACE2 and the high frequency of asymptomatic infections compared  
314 to adults<sup>42-44</sup>. This notion has been debated in research<sup>11,45-48</sup>, and is critical for making decisions  
315 related to epidemic control measurements, like school-closure. In our study, we found that children  
316 <12 years had a similar probability to become infected as adults. Almost half of the child cases in our  
317 study were asymptomatic, their viral load at study start was similar to that of adults, and other studies  
318 have shown that 40-80% of transmission events take place before symptom onset<sup>49-51</sup>. A study looking  
319 at the viral shedding of asymptomatic, presymptomatic and symptomatic children did not find a  
320 difference in viral shedding between these groups<sup>52</sup>. Together, these findings imply that children may  
321 play a larger role in transmission of SARS-CoV-2 than is currently thought. A prospective cohort  
322 study in which MLF samples are collected irrespective of symptom presentation would provide more  
323 insight in whether (asymptomatic) infections in children are an important driver of household  
324 transmission or not. Since collection of MLF for antibody analysis is rapid, non-invasive and can be  
325 done by study participants in the absence of health care professionals, such studies including repetitive  
326 sampling are feasible in this age group.

327

328 Our study has several limitations. First, the starting point for our study was the inclusion of healthcare  
329 workers, most of whom were female, and not entirely representative for the larger population. It  
330 should be noted that this study was performed during the first wave in March-April of 2020, when all  
331 schools in the Netherlands were closed (**Figure 1b**), minimizing contacts between children and thus  
332 making it hard to study the role of child-child contacts in the transmission of SARS-CoV-2. Lastly,  
333 additional mucosal lining fluid measurements would have enabled more advanced modelling of the  
334 mucosal antibody trajectories, especially in the household contacts.

335

336 This study provides an example of the unique possibilities of studying mucosal antibody trajectories. It  
337 provides essential new insights into the mucosal antibody kinetics after a SARS-CoV-2 infection, and  
338 uncovers novel relations with viral load and symptom resolution. Furthermore, the study design and  
339 analysis strategy presented here can be used as a blueprint for follow-up investigations not only for  
340 COVID-19, but also for other infectious diseases. The ability to collect repetitive mucosal antibody  
341 samples in a non-invasive manner removes an important obstacle for use in age groups that are  
342 normally difficult to sample, such as children.

## 343 **ONLINE METHODS**

### 344 **Recruitment**

345 This observational prospective cohort study was conducted among COVID-19 cases with a laboratory  
346 confirmed infection, as well as their household members that remained in home quarantine at the same  
347 address. The study was conducted in accordance with the provisions of the Declaration of Helsinki  
348 (1996) and the International Conference on Harmonization Guidelines for Good Clinical Practice. The  
349 study was approved by the local medical research ethics committee and is registered with  
350 ClinicalTrials.gov (NCT04590352; ethical committee reference NL73418.091.20). All index cases in  
351 this study were healthcare workers (HCW) from three hospitals (Radboudumc, CWZ and Rijnstate) in  
352 the provinces of Gelderland in the Netherlands, with a confirmed SARS-CoV-2 infection. Study  
353 participants were included from the 26<sup>th</sup> of March 2020 until the 15<sup>th</sup> of April, when the inclusion  
354 number of 50 households was reached. Participants were introduced to the study through the  
355 occupational health and safety services (OHS) of the participating hospitals. HCWs were included if  
356 they had a positive Polymerase Chain Reaction test (PCR-test) for the SARS-CoV-2 virus, tested and  
357 judged by the OHS of their hospital, with a positive indication for home isolation, and had at least two  
358 household members willing to participate.

359

### 360 **Study design**

361 Before the first home visit, all index cases of the family had a telephone interview, where they were  
362 asked about their first day of symptom onset, whether they were in isolation from the rest of the  
363 household, whether physical contact was restricted with other household members, whether they were  
364 still symptomatic, and whether they thought they were the primary case in the household. Households  
365 were visited within 1-2 days of a positive PCR in the index case. Following informed consent,  
366 nasopharyngeal and oropharyngeal swabs were taken for viral PCR, as per diagnostic guidelines<sup>53</sup>. A  
367 nasal mucosal lining fluid (MLF) sample was obtained from all participants by the use of the  
368 Nasosorption™ FX·i nasal sampling device (Hunt Developments, UK). A synthetic absorptive matrix  
369 (SAM) strip was gently inserted into the nostril of the participant and placed along the surface of the  
370 inferior turbinate. The index finger was lightly pressed against the side of the nostril to keep the SAM  
371 strip in place and to allow MLF absorption for 60 seconds, after which the SAM strip was placed back  
372 in the protective plastic tube. Participants were instructed on how to self-sample MLF at home.  
373 Finally, participants were asked about their symptoms of that day.

374 Participants were followed up for approximately 28 days, starting on the day of the first home visit  
375 (day 0) and ending on the last home visit (day 28-33). This range in the last visit was due to logistical  
376 difficulties during the summer holidays; 14 index cases were visited on their day 29, three on day 30,  
377 five on day 31, four on day 32 and one on day 33. All participants registered their symptoms for 28  
378 days. During follow-up, clinical symptoms were registered three times daily and MLF was collected at  
379 three different study days via self-sampling. For the index case, MLF was collected on day 0, 3, 6 and

380 28-33 and for the household contacts this was on day 0, 7, 14 and 28-33 (**Figure 1c**). Self-sampled  
381 MLF samples were stored in biosafety bags in the participants' own freezer (temperature around -20  
382 °C).

383 At the final home visit, MLF samples were picked up and transported to the Radboudumc on dry ice,  
384 where it was stored at -80°C until further testing. For antibody analysis, Nasosorption™ FX-i nasal  
385 sampling devices were thawed on ice, after which the synthetic adsorptive matrix (SAM) was removed  
386 using sterile forceps. The SAM was placed in a spin-X filter Eppendorf tube with 300uL of elution  
387 buffer (PBS/1% BSA) for a minimum of 10 minutes, followed by centrifugation at 16000xg for 10  
388 minutes at 4°C. To prevent unspecific binding, the spin-X filter columns were pre-incubated with the  
389 blocking buffer for 30 minutes. The filter cups were then removed from the Eppendorf tubes using  
390 sterile forceps. To inactivate live SARS-CoV-2, the eluate was incubated for a minimum of 45  
391 minutes at 56 °C, spun down, aliquotted and stored at -20°C for further testing.

392 Finger-prick blood (~0.3 ml) was collected from all participants consenting to the finger-prick at day  
393 28 by the use of a sterile disposable lancet device (BD Microtainer Lancet) and a sterile capillary tube.  
394 Blood samples were kept at room temperature until processing at the Radboudumc laboratory site,  
395 after which serum was stored at -20°C until further testing.

396 All collected symptom diaries were digitalized into Castor EDC, clinical trial software for electronic  
397 data capture and clinical data management.

398

### 399 **Sample analysis**

#### 400 ***Detection of SARS-CoV-2***

401 Presence or absence of SARS-CoV-2 and viral copy number per ml was determined on the combined  
402 nasopharyngeal and oropharyngeal swab, using a PCR protocol that was developed at the  
403 Radboudumc Medical Microbiology Laboratory. Nasopharyngeal and oropharyngeal swabs were  
404 collected in GLY medium and stored at -80°C until processing. Samples were thawed, vortexed and  
405 500 ul of sample was lysed in 450 ul MagNAPure Lysis/binding buffer (Roche). An ivRNA internal  
406 extraction control was added and samples were extracted on the automated MagNAPure LC2.0 system  
407 using the MagNAPure LC Total Nucleic Acid isolation kit - High Performance (Roche). Samples were  
408 eluted in 50 ul of which 5 ul was used in the RT-qPCR using the Luna Universal Probe One-Step RT-  
409 qPCR kit (NEB) with 400 nM E-gene primers (FW: 5'- acaggtacgttaatagtaatagcgt-3' RV: 5'-  
410 atattgcagcagctacgcacaca-3') and 200 nM E-gene probe (5'-FAM-  
411 AACTAGCCATCCTTACTGCGCTTCG-BHQ1-3' (Biolegio)) on a CFX96 Real-Time PCR  
412 Detection System (BioRad). Transcript quantities were calculated using a 10-fold dilution series of E-  
413 gene ivRNA. The extraction efficiency was checked in a separate RT-qPCR using the Luna Universal  
414 Probe One-Step RT-qPCR kit (NEB) with primers targeting the ivRNA that was added prior to  
415 extraction.

#### 416 ***Antibody measurements***

417 For antibody analysis, a fluorescent-bead-based multiplex immunoassay (MIA) was developed. The  
418 stabilized pre-fusion conformation of the ectodomain of the Spike protein (amino acids 1 – 1,213)  
419 fused with the trimerization motif GCN4 (S-protein) and the receptor binding domain of the S-protein  
420 (RBD) as previously described by Wang C. et al.<sup>54</sup>, and the Nucleocapsid-His recombinant Protein (N)  
421 (40588-V08B, Sino Biologicals), were each coupled to beads or microspheres with distinct  
422 fluorescence excitation and emission spectra, essentially as described in the paper by den Hartog *et*  
423 *al.*<sup>55</sup>

424 A total of six reference serum samples were selected from PCR confirmed COVID-19 patients with  
425 varying immunoglobulin G (IgG) concentrations, and pooled to create standard curves for IgG, IgA  
426 and IgM. Next to this, four different samples from the same cohort were used as quality control  
427 samples. As negative control samples, we used historical serum (n=32) and MLF (n=17) samples  
428 collected prior to the SARS-CoV-2 pandemic.

429 MLF samples were diluted 1:5 in assay buffer (PBS/1% BSA/0.05% tween-20) and serum samples  
430 were diluted 1:500 in assay buffer, incubated with antigen-coated microspheres for 30 minutes at room  
431 temperature while shaking at 450 rpm. Following incubation, the microspheres were washed two times  
432 with PBS, incubated with phycoerythrin-conjugated goat anti-human, IgG (Jackson ImmunoResearch,  
433 109-116-170), IgM (Southern Biotech, 2022-09) and IgA (Southern Biotech, 2052-09) for 20 minutes  
434 and washed twice. Data were acquired on the Luminex FlexMap3D System. Validation of the  
435 detection antibodies was obtained from a recent publication using the same antibodies and the same  
436 assay<sup>55</sup>, and specificity was checked using rabbit anti-SARS SIA-ST serum.

437 S- and N-coupled microspheres were combined to measure antibodies directed against multiple  
438 antigens (or epitopes) in one single sample. Since antibodies against the S-protein and RBD may  
439 compete for the same epitopes, antibody binding to RBD was measured separately. Using different  
440 conjugates, IgG, IgA, and IgM-specific antibodies concentrations were measured in MLF and serum.  
441 MFI was converted to arbitrary units (AU/ml) by interpolation from a log-5PL-parameter logistic  
442 standard curve and log-log axis transformation, using Bioplex Manager 6.2 (Bio-Rad Laboratories)  
443 software and exported to R-studio. Negative control samples (MLF and serum) were used to filter out  
444 background signal in the antibody measures. The MLF samples originated from the KIRA-study  
445 performed at the Radboudumc, in which healthy healthcare workers are vaccinated against pertussis as  
446 per routine care, and gave consent to the use of the MLF samples for other research. The serum  
447 samples originated from the Radboudumc Biobank, that allows the use of serum samples for research  
448 as long as privacy of the donors is guaranteed. The standard dilution range plus four quality control  
449 samples were added to each plate.

450

### 451 **Symptom categorization**

452 To analyse the relation between symptom clearance in index cases and the mucosal antibody response,  
453 we categorized our set of symptoms into three categories, based on their clinical presentation. This

454 resulted in a set of 23 symptoms, which were categorized into three categories, i.e. respiratory  
455 symptoms (RS) systemic disease symptoms (SDS), and gastrointestinal symptoms (GS). RS includes  
456 chest pain, sneezing, nose bleeding, pain when breathing, coughing with mucus, dyspnoea, sore throat,  
457 loss or change of taste/smell (dysnosmia), coughing, and rhinorrhoea. SDS includes dizziness,  
458 headache, fever, temperature, chills, joint pain, muscle pain, swollen lymph nodes and low appetite.  
459 GS includes vomiting, diarrhoea, and nausea. Because fatigue was reported in almost all cases, we did  
460 not categorize it into one of the symptom categories.

461

### 462 **Case definition and cluster identification**

463 For analysis of SARS-CoV-2 exposure within households, we categorized the household contacts into  
464 cases and controls. Cases were defined as being either PCR positive at study start and/or seropositive  
465 for IgA, IgG or IgM against S at the end of follow-up. PCR positivity was set on a Ct value < 36, which  
466 corresponds to a viral load of at least  $10^3$  copies/ml extracted sample. The seroconversion threshold  
467 was based on the mean + 2\*SD of the historic negative control samples, which were collected before  
468 SARS-CoV-2 was introduced in the Netherlands. Additionally, we used a Naïve Bayesian  
469 probabilistic model (R-package “naivebayes”, with prior probabilities derived as the class proportions  
470 for the training set, and Laplace smoothing set at 1) to identify cases within the PCR/seronegative  
471 contacts by the anti-S MLF antibody response on day 28. Mucosal antibody levels from PCR positive  
472 cases were used as positive controls; mucosal antibody levels from the historic cohort samples as  
473 negative controls. These values were used to train the probabilistic model, after which the model was  
474 applied to the PCR/seronegative contacts.

475

### 476 **Statistical analyses**

477 Analysis of Luminex data was performed with Bio-Plex 200 in combination with Bio-Plex manager  
478 software (Bio-Rad Laboratories, Hercules, CA). Demographical data was exported from Castor EDC,  
479 and double checked with the paper records by two members of the research team. All statistical  
480 analyses were performed using the Rstudio environment, with libraries ‘stats’ (hypothesis tests and  
481 correlations), “naivebayes” for the naïve Bayes classification, “lme4”<sup>56</sup>, “lmerTest”<sup>57</sup> for mixed-  
482 effects modelling and associated p-values, and “survival”<sup>58</sup> for Kaplan-Meier survival analysis. The  
483 libraries “survminer” and “ggplot2” were used for visualization. Changes in serum or mucosal  
484 antibodies compared to negative controls were tested using a two-tailed paired Wilcoxon signed rank  
485 test, and then corrected for multiple testing with the Benjamini-Hochberg method<sup>59</sup>. Statistical  
486 parameters including the sample sizes, measures of distribution, and p-value thresholds for  
487 significance are reported directly in the figures and figure legends. In order to determine if a sample  
488 was seropositive for a given combination of antigen and antibody isotype, a cut-off value (mean + 2  
489 standard deviations) was calculated from the negative control samples. Samples above this threshold  
490 were classified as seropositive for that antigen and isotype combination. Samples that were



491 seropositive for any of the antibodies tested were classified as such (“anySero”, Figure 2A). Where  
492 correlations are presented, the spearman correlation coefficient and associated p-value were calculated.  
493 The time at which a subject became symptom-free was calculated as the last day that individual  
494 showed symptoms for that category, plus one day. The probability of becoming symptom-free was  
495 estimated using Kaplan-Meier’s method, and the hypothesis testing was performed using log-rank test.  
496 In order to estimate the effect of patient characteristics and antibodies on symptoms over time, we  
497 constructed a mixed-effects model. For each subject and for each timepoint, we added together the  
498 number of complaints per symptom category. We specified a mixed-effects model per symptom  
499 category with symptoms as the response and time since symptom onset (POS), age, and sex, as  
500 explanatory variables. We also added POS and Sample\_ID as random effects. The formula for the  
501 model (in R notation):

502  
503  $\text{Symptom\_count} \sim \text{POS} + \text{Age} + \text{Sex} + (\text{POS} | \text{Sample\_ID})$

504  
505 In order to determine the effect of antibodies on the symptom response, the model above was updated  
506 in a univariate fashion with each antibody measurement as a covariate. The formula of the updated  
507 model:

508  
509  $\text{Symptom\_count} \sim \text{POS} + \text{Age} + \text{Sex} + \text{Antibody} + (\text{POS} | \text{Sample\_ID}).$

510 Estimates for the covariates, as well as 95% confidence intervals and p-values (Satterthwaite’s  
511 approximation to degrees of freedom) were extracted and plotted.

512  
513 **FUNDING**

514 This study was funded by the Laboratory of Medical Immunology, Radboud university medical center.  
515

516 **DATA AND CODE AVAILABILITY STATEMENT**

517 The data and R-code that support the findings of this study are available from the corresponding  
518 author upon reasonable request.

519  
520 **CONTRIBUTORS**

521 Conceptualization: D.A.D and M.I.J.; investigation: J.F., D.A.D., R.P., J.R., D.T., and M.B.; lab  
522 processing: J.F., R.P., D.A.D., K.L., E.S., and C.E.G.-J.; formal analysis: J.F. and J.G.; writing—  
523 original draft preparation: J.F., and J.G.; writing—review and editing: J.G, D.A.D., T.B., M.A.H.,  
524 M.I.J., and R.P.; resources: F.J.K, B.-J.B., N.G.-B, C.D., and M.N.-F.; and supervision: D.A.D.

525  
526 **DECLARATION OF INTERESTS**

527 There are no competing interests to be declared.

528 **ACKNOWLEDGEMENTS**

529 We would like to thank all MuCo study participants for their willingness to participate and their  
530 support for the study. Additionally, we thank M. Boonstra, M. Blok, D. van der Giessen, E. Lenssen,  
531 E. Reuvers, M. Roek and E. Wijnhoven for assisting with performing the first home visit, H. Lyoo  
532 from Utrecht university for experimental assistance, J. Heijnen, M. Dautzenberg, and A. Voss for  
533 recruiting participants from the occupational health and safety officers at Rijnstate and CWZ  
534 hospitals, and the respective medical microbiology departments involved in PCR testing of hospital  
535 employees.

536

537

538

539 **FIGURE LEGENDS**

540 **Figure 1. Flow diagram and study procedures.** **a)** Flow diagram describing the recruitment of  
541 households, sample sizes, and study outcomes. We initially contacted 97 index cases that were tested  
542 positive for SARS-CoV-2. After exclusion of cases that did not meet the inclusion criteria or did not  
543 consent, 50 index cases and their household contacts (N=137) were recruited. Mucosal lining fluid  
544 (MLF) antibodies were analysed as a primary outcome in both indexes and household contacts.  
545 Secondary analyses (correlation of MLF antibodies with viral load and symptoms, serology,  
546 estimation of SARS-CoV-2 exposure) were performed. **b)** Study timeline, with respect to the number  
547 of hospitalizations due to COVID-19 over time and COVID-19 control measures in the  
548 Netherlands<sup>60,61</sup>. The first home visit was conducted at the peak of hospitalizations at March 26, and  
549 the last visit was one day after the reopening of primary schools, at May 13. **c)** Overview of the study  
550 design and measurements. Home visits were initiated after the index was tested positive for SARS-  
551 CoV-2 by PCR, to collect naso- and oropharyngeal swabs for viral load determination as well as nasal  
552 MLF samples. Subsequent MLF samples were collected and stored by the participants, who also  
553 completed a daily symptom survey. At the end of the study, blood samples were collected for  
554 serological analyses.

555  
556

557 **Figure 2. Serum antibody responses against SARS-CoV-2 in COVID-19 patients and household**  
558 **contacts.** **a)** Seroconversion heatmap for index cases (N=50) and contacts (N=129) for each antigen  
559 and antibody isotype measurement, as well as seroconversion rate for any single antibody  
560 measurement (anySero). Seroconversion threshold was calculated as the mean of the controls plus  
561 2\*standard deviation. **b)** Serum antibody responses against SARS-CoV-2 in COVID-19 in index cases  
562 correlated with mucosal antibody responses. IgM, IgG, and IgA antibody responses against SARS-  
563 CoV-2 spike protein (S), receptor binding domain (RBD) and nucleocapsid (N) were measured in sera  
564 or in mucosal lining fluid at the end of the study. Antibody levels are expressed as a ratio compared to  
565 the mean of pre-corona samples (relative ratio). Data are shown for index cases (N=50). Spearman  
566 correlations were calculated and p-values are reported directly in the figure.

567  
568

569 **Figure 3. Mucosal antibody responses during SARS-CoV-2 infection in index cases (N=49).** **a)**  
570 IgM, IgG and IgA antibody responses against SARS-CoV-2 spike (S), receptor binding domain (RBD)  
571 or nucleocapsid (N) collected in mucosal lining fluid at d0 were correlated with days since symptom  
572 onset (PSO) and viral load. Spearman correlations were calculated, \* p <0.05, \*\*p<0.01, \*\*\* p<0.001.  
573 p-values of borderline significant tests are reported directly in the figure. **b)** Longitudinal mucosal  
574 antibody responses to S, RBD and N, plotted relative to the days PSO. Pre-SARS-CoV-2 controls are  
575 presented in the grey boxplots for comparison (n=17). Values within each timeframe were compared

576 with the controls with the Wilcoxon-signed rank test. A non-parametric Loess curve is shown as red  
577 line to visualize the trend over time. Measurements from the same individual are connected with a  
578 grey line. c) Antibody measurements within the depicted timeframes were correlated with each other.  
579 Spearman correlation coefficient is presented.

580

581

582 **Figure 4. Influence of age and mucosal antibody levels on the progression of systemic and**  
583 **respiratory COVID-19 symptoms. a)** The number of respiratory (RS) and systemic disease (SDS)  
584 symptoms were recorded for index cases (N = 49) for each day during the 28 day study period. Data  
585 are plotted relative to the time of symptom onset and values were binned into 3-day time frames. A  
586 non-parametric loess curve is shown as a red (SDS) or blue (RS) line in order to visualize the trend  
587 over time. **b)** A linear mixed-effect model (MEM) was fit to the data per symptom group. The  
588 response was specified as the number of symptoms on a given day, and explanatory fixed effects  
589 variables were: day since symptom onset, age, and sex. Time since symptom onset was also specified  
590 as a random slope, and Sample ID as a random intercept. A significant effect of age ( $p = 0.0165$ ) was  
591 demonstrated for RS. Predicted symptom values from the model are plotted against index case age  
592 with 95% confidence interval bands. **c)** Longitudinal mucosal antibody measurements were added as  
593 fixed effect variables in a univariate fashion to the MEM from b). The predicted change in symptoms  
594 per unit increase of antibody signal is presented with 95% confidence intervals, and p-values for the  
595 association are plotted on the right (\*  $p < 0.05$ ; \*\*  $p < 0.01$ ; \*\*\*  $p < 0.001$ ).

596

597

598 **Figure 5 Identification of household contact cases and assessment of their mucosal SARS-CoV-2**  
599 **antibody responses. a)** Contact cases were classified into case or non-case first by their PCR result on  
600 enrolment, followed by seroconversion for either IgM, IgG or IgA against the S-protein, and mucosal  
601 antibody levels for either IgM, IgG or IgA against the S-protein at the end of the follow-up. The PCR  
602 positive threshold was set at a Ct value  $< 36$ . The seroconversion threshold was based on the mean +  
603  $2 \times \text{SD}$  of the log<sub>2</sub>-transformed pre-SARS-CoV-2 control samples. To identify cases based on mucosal  
604 antibodies against S, we used a naive Bayes model that was trained by the mucosal antibody  
605 measurements of the positive study participants (cases) and the pre-SARS-CoV-2 control samples  
606 (controls). **b)** Contacts were classified by their household as either the primary (N=9) or a non-primary  
607 (N=58) case, based on time of symptom onset. Mucosal antibody responses of the primary household  
608 contact cases collected at d0 were correlated with viral load. Spearman correlations were calculated, \*  
609  $p < 0.05$ , \*\*  $p < 0.01$ , \*\*\*  $p < 0.001$ . p-values of borderline significant tests are reported directly in the  
610 figure. **c)** IgM, IgG and IgA antibody responses against Spike protein (S), receptor binding domain  
611 (RBD) and nucleocapsid (N), measured in mucosal lining fluid. Data are plotted relative to the time of  
612 symptom onset of the index case in the respective household, and pre-SARS-CoV-2 control samples

613 are presented for comparison. A non-parametric loess curve is shown as a red (primary cases) and a  
614 blue (non-primary cases) line to visualize the trend over time.

615

616

617 **Figure 6. SARS-CoV-2 infection, viral load and number of symptoms of contact cases, split into**

618 **four age groups. a)** Proportion of infected household contacts per age group. Sixteen out of 33

619 primary school-age children (1-12y) were infected (48%), 13 out of 23 children aged 13-18y (56%),

620 27 out of 50 adults aged 19-49 years (54%) and 19 out of 31 contacts older than 50 years (61%). **b)**

621 Proportion of asymptomatic disease among household cases (N=75) at study enrolment within each

622 age category. Seven of the children below 12 years were asymptomatic (44%), two of the children up

623 to 18 years (15%), seven of the adults up to 49 years (28%) and two of the contacts older than 50 years

624 (11%). **c)** The correlation between the total number of reported symptoms and the age of the infected

625 household contacts. Pearson's correlation and significance is depicted in the figure. The shape of the

626 datapoints represents the method by which a contact was classified as a case and the color of the

627 datapoints shows the viral load at study start.

628

629

630 **Figure S1. Serum antibody responses against Sars-CoV-2 in COVID-19 patients and household**

631 **contacts.** IgM, IgG, and IgA serum antibody responses against Sars-CoV-2 spike protein (S), receptor

632 binding domain (RBD), or nucleocapsid (N). Data are shown for pre-SARS-Cov-2 control samples

633 (N=32), index cases (N=50), or household contacts (N=129). Antibody levels are expressed as a ratio

634 compared to the mean of the controls (relative ratio) and values of indexes and contacts were

635 compared to those of controls using a Wilcoxon signed rank test, \*  $p < 0.05$ ; \*\*  $p < 0.01$ ; \*\*\*  $p < 0.001$ ,

636 and a threshold for seroconversion (dotted line) was calculated based on the mean + 2\*sd of the

637 control samples.

638

639

640 **Figure S2. Timing of COVID-19 patient recruitment and sample measurements relative to**

641 **symptoms onset. a)** The graph shows the cumulative percentage of households (N=50) included at a

642 given time post symptom onset. **b)** Overview of the measurements made for the index cases relative to

643 the reported first day of symptom onset. Each line represents one participant.

644

645 **Figure S3. SARS-CoV-2 viral load at different days post symptom onset.** Index cases (N=49) were

646 asked when their symptoms started, and viral load was measured at study start. Individuals are binned

647 together based on their reported symptom onset, relative to the study start. The y-axis shows the

648 average viral load in log<sub>10</sub> copies/ml extracted sample.

649

650 **Figure S4. Clinical presentation of mild COVID-19 disease. a)** Index cases (N = 49) completed a  
651 daily symptom survey covering 23 symptoms for 28 days during the study period. The number of  
652 index cases that reported a given symptom at any time during the study period is presented. Symptoms  
653 were categorized into either respiratory symptoms (RS), systemic disease symptoms (SDS), or  
654 gastrointestinal symptoms (GS). Fatigue was not categorized. **b)** Cumulative symptoms per symptom  
655 group for each study day are plotted for each index case. Data are represented since the time of  
656 symptom onset. A window depicts the study period for a given index case. **c)** Symptom durations were  
657 calculated for RS and SDS, and compared using a Kaplan Meier analysis. The probability of becoming  
658 symptom-free at a given time post-symptom onset is depicted. The log-rank p-value represents the  
659 statistical difference between resolution of SDS and RS.

660

661

662 **Figure S5. Mixed-effects modelling of longitudinal symptom data in COVID-19 patients.** The  
663 number of respiratory (RS) and systemic disease (SDS) symptoms were determined for index cases (N  
664 = 49) for each day during the 28 day study period. Data are represented relative to the time of  
665 symptom onset. A linear mixed-effect model was fit to the data per symptom group. The response was  
666 specified as the number of symptoms on a given day, and explanatory fixed effects variables were: day  
667 since symptom onset, age, and sex. Time since symptom onset was also specified as a random slope,  
668 and Sample ID as a random intercept. Datapoints are plotted per day and joined by a faded line,  
669 predicted values from the mixed-effects model are plotted on top as solid straight lines.

670

671

672 **Figure S6. Viral load and anti-Spike serum antibody concentrations in household contact cases  
673 of different age categories. a)** Viral load at study enrolment, depicted for the PCR positive household  
674 cases (n=46). The y-axis shows the average viral load in log<sub>10</sub> copies/ml extracted sample of the  
675 contact cases, the x-axis shows the four different age categories. **b)** Serum anti-Spike protein levels at  
676 the end of the study, for IgA, IgM and IgG, in each age category. Serum antibody levels are depicted  
677 as the log<sub>10</sub> antibody concentration in AU/ml. Only infected household members were selected  
678 (n=75).

679 **REFERENCES**

- 680 1. Lewis NM, Duca LM, Marcenac P, et al. Early Release-Characteristics and Timing of Initial  
681 Virus Shedding in Severe Acute Respiratory Syndrome Coronavirus 2, Utah, USA.
- 682 2. Grijalva CG, Rolfes MA, Zhu Y, et al. Transmission of SARS-CoV-2 infections in households—  
683 Tennessee and Wisconsin, April–September 2020. *Morbidity and Mortality Weekly Report* 2020;  
684 **69**(44): 1631.
- 685 3. Tosif S, Neeland MR, Sutton P, et al. Immune responses to SARS-CoV-2 in three children of  
686 parents with symptomatic COVID-19. *Nature Communications* 2020; **11**(1): 5703.
- 687 4. Wölfel R, Corman VM, Guggemos W, et al. Virological assessment of hospitalized patients  
688 with COVID-2019. *Nature* 2020.
- 689 5. Lee S, Kim T, Lee E, et al. Clinical Course and Molecular Viral Shedding Among Asymptomatic  
690 and Symptomatic Patients With SARS-CoV-2 Infection in a Community Treatment Center in the  
691 Republic of Korea. *JAMA Intern Med* 2020.
- 692 6. To KK, Tsang OT, Leung WS, et al. Temporal profiles of viral load in posterior oropharyngeal  
693 saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational  
694 cohort study. *Lancet Infect Dis* 2020.
- 695 7. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease  
696 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center  
697 for Disease Control and Prevention. *Jama* 2020.
- 698 8. Kim G-u, Kim M-J, Ra SH, et al. Clinical characteristics of asymptomatic and symptomatic  
699 patients with mild COVID-19. *Clinical Microbiology and Infection* 2020.
- 700 9. Oran DP, Topol EJ. Prevalence of Asymptomatic SARS-CoV-2 Infection: A Narrative Review.  
701 *Ann Intern Med* 2020.
- 702 10. RIVM. Epidemiologische situatie COVID-19 in Nederland: Rijksinstituut voor Volksgezondheid  
703 en Milieu, 2020.
- 704 11. Gandhi M, Yokoe DS, Havlir DV. Asymptomatic transmission, the Achilles’ heel of current  
705 strategies to control COVID-19. *Mass Medical Soc*; 2020.
- 706 12. WHO. Public health surveillance for COVID-19 WHO, 2020.
- 707 13. Arons MM, Hatfield KM, Reddy SC, et al. Presymptomatic SARS-CoV-2 infections and  
708 transmission in a skilled nursing facility. *New England journal of medicine* 2020.
- 709 14. Mizrahi B, Shilo S, Rossman H, et al. Longitudinal symptom dynamics of COVID-19 infection in  
710 primary care. *medRxiv* 2020.
- 711 15. Voysey M, Clemens SAC, Madhi SA, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine  
712 (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil,  
713 South Africa, and the UK. *The Lancet* 2020.
- 714 16. Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA covid-19  
715 vaccine. *New England Journal of Medicine* 2020.
- 716 17. Dutta NK, Mazumdar K, Gordy JT. The nucleocapsid protein of SARS–CoV-2: a target for  
717 vaccine development. *Journal of virology* 2020; **94**(13).
- 718 18. McAndrews KM, Dowlathshahi DP, Dai J, et al. Heterogeneous antibodies against SARS-CoV-2  
719 spike receptor binding domain and nucleocapsid with implications for COVID-19 immunity. *JCI insight*  
720 2020; **5**(18).
- 721 19. Zhao J, Yuan Q, Wang H, et al. Antibody responses to SARS-CoV-2 in patients of novel  
722 coronavirus disease 2019. *Clin Infect Dis* 2020.
- 723 20. Carsetti R, Zaffina S, Piano Mortari E, et al. Spectrum of innate and adaptive immune  
724 response to SARS CoV 2 infection across asymptomatic, mild and severe cases; a longitudinal cohort  
725 study. *medRxiv* 2020.
- 726 21. Rijkers G, Murk J-L, Wintermans B, et al. Differences in antibody kinetics and functionality  
727 between severe and mild SARS-CoV-2 infections. *medRxiv* 2020.
- 728 22. Marklund E, Leach S, Axelsson H, et al. Serum-IgG responses to SARS-CoV-2 after mild and  
729 severe COVID-19 infection and analysis of IgG non-responders. *medRxiv* 2020.


- 730 23. Wajnberg A, Amanat F, Firpo A, et al. SARS-CoV-2 infection induces robust, neutralizing  
731 antibody responses that are stable for at least three months. *medRxiv* 2020.
- 732 24. Du L, Zhao G, Lin Y, et al. Intranasal vaccination of recombinant adeno-associated virus  
733 encoding receptor-binding domain of severe acute respiratory syndrome coronavirus (SARS-CoV)  
734 spike protein induces strong mucosal immune responses and provides long-term protection against  
735 SARS-CoV infection. *J Immunol* 2008; **180**(2): 948-56.
- 736 25. Lee J-S, Poo H, Han DP, et al. Mucosal Immunization with Surface-Displayed Severe Acute  
737 Respiratory Syndrome Coronavirus Spike Protein on *Lactobacillus casei* Induces  
738 Neutralizing Antibodies in Mice. *Journal of Virology* 2006; **80**: 4079-87.
- 739 26. Pisanic N, Randad PR, Kruczynski K, et al. COVID-19 serology at population scale: SARS-CoV-2-  
740 specific antibody responses in saliva. *J Clin Microbiol*; (JCM.02204-20).
- 741 27. Isho B, Abe KT, Zuo M, et al. Persistence of serum and saliva antibody responses to SARS-  
742 CoV-2 spike antigens in COVID-19 patients. *Science immunology* 2020; **5**(52).
- 743 28. Cervia C, Nilsson J, Zurbuchen Y, et al. Systemic and mucosal antibody secretion specific to  
744 SARS-CoV-2 during mild versus severe COVID-19. *bioRxiv* 2020.
- 745 29. Seow J, Graham C, Merrick B, et al. Longitudinal evaluation and decline of antibody responses  
746 in SARS-CoV-2 infection. *medRxiv* 2020.
- 747 30. Lechien JR, Chiesa-Estomba CM, Place S, et al. Clinical and epidemiological characteristics of  
748 1,420 European patients with mild-to-moderate coronavirus disease 2019. *Journal of internal*  
749 *medicine* 2020.
- 750 31. Faustini SE, Jossi SE, Perez-Toledo M, et al. Detection of antibodies to the SARS-CoV-2 spike  
751 glycoprotein in both serum and saliva enhances detection of infection. *medRxiv* 2020.
- 752 32. Butler SE, Crowley AR, Natarajan H, et al. Features and Functions of Systemic and Mucosal  
753 Humoral Immunity Among SARS-CoV-2 Convalescent Individuals. *medRxiv* 2020.
- 754 33. Sterlin D, Mathian A, Miyara M, et al. IgA dominates the early neutralizing antibody response  
755 to SARS-CoV-2. *Science Translational Medicine* 2020.
- 756 34. Le Bert N, Tan AT, Kunasegaran K, et al. SARS-CoV-2-specific T cell immunity in cases of  
757 COVID-19 and SARS, and uninfected controls. *Nature* 2020; **584**(7821): 457-62.
- 758 35. Mateus J, Grifoni A, Tarke A, et al. Selective and cross-reactive SARS-CoV-2 T cell epitopes in  
759 unexposed humans. *Science* 2020; **370**(6512): 89-94.
- 760 36. Li L, Tong X, Chen H, et al. Characteristics and serological patterns of COVID-19 convalescent  
761 plasma donors: optimal donors and timing of donation. *Transfusion* 2020; **60**(8): 1765-72.
- 762 37. Rojas M, Rodríguez Y, Monsalve DM, et al. Convalescent plasma in Covid-19: Possible  
763 mechanisms of action. *Autoimmunity Reviews* 2020; **19**(7): 102554.
- 764 38. Gasser R, Cloutier M, Prévost J, et al. Major role of IgM in the neutralizing activity of  
765 convalescent plasma against SARS-CoV-2. *bioRxiv* 2020.
- 766 39. Bi Q, Wu Y, Mei S, et al. Epidemiology and transmission of COVID-19 in 391 cases and 1286 of  
767 their close contacts in Shenzhen, China: a retrospective cohort study. *The Lancet Infectious Diseases*  
768 2020.
- 769 40. Koh WC, Naing L, Rosledzana MA, et al. What do we know about SARS-CoV-2 transmission? A  
770 systematic review and meta-analysis of the secondary attack rate, serial interval, and asymptomatic  
771 infection. *medRxiv* 2020.
- 772 41. Lopez Bernal J, Panagiotopoulos N, Byers C, et al. Transmission dynamics of COVID-19 in  
773 household and community settings in the United Kingdom. *medRxiv* 2020.
- 774 42. Bunyavanich S, Do A, Vicencio A. Nasal gene expression of angiotensin-converting enzyme 2  
775 in children and adults. *Jama* 2020.
- 776 43. Dong Y, Mo X, Hu Y, et al. Epidemiology of COVID-19 among children in China. *Pediatrics*  
777 2020; **145**(6).
- 778 44. She J, Liu L, Liu W. COVID-19 epidemic: disease characteristics in children. *Journal of medical*  
779 *virology* 2020.
- 780 45. Dub T, Erra E, Hagberg L, et al. Transmission of SARS-CoV-2 following exposure in school  
781 settings: experience from two Helsinki area exposure incidents. *medRxiv* 2020.



- 782 46. Han MS, Choi EH, Chang SH, et al. Clinical Characteristics and Viral RNA Detection in Children  
783 With Coronavirus Disease 2019 in the Republic of Korea. *JAMA Pediatrics* 2021; **175**(1): 73-80.
- 784 47. Kelvin AA, Halperin S. COVID-19 in children: the link in the transmission chain. *The Lancet*  
785 *Infectious Diseases* 2020.
- 786 48. Lee B, Raszka WV. COVID-19 transmission and children: the child is not to blame. *Pediatrics*  
787 2020; **146**(2).
- 788 49. Tindale LC, Stockdale JE, Coombe M, et al. Evidence for transmission of COVID-19 prior to  
789 symptom onset. *Elife* 2020; **9**: e57149.
- 790 50. Cheng H-Y, Jian S-W, Liu D-P, Ng T-C, Huang W-T, Lin H-H. Contact tracing assessment of  
791 COVID-19 transmission dynamics in Taiwan and risk at different exposure periods before and after  
792 symptom onset. *JAMA internal medicine* 2020.
- 793 51. Moghadas SM, Fitzpatrick MC, Sah P, et al. The implications of silent transmission for the  
794 control of COVID-19 outbreaks. *Proceedings of the National Academy of Sciences* 2020; **117**(30):  
795 17513-5.
- 796 52. Han MS, Choi EH, Chang SH, et al. Clinical characteristics and viral RNA detection in children  
797 with coronavirus disease 2019 in the Republic of Korea. *JAMA pediatrics* 2020.
- 798 53. Richtlijnen COVID-19. 2020. <https://ici.rivm.nl/richtlijnen/covid-19> (accessed January 14  
799 2021).
- 800 54. Wang C, Li W, Drabek D, et al. A human monoclonal antibody blocking SARS-CoV-2 infection.  
801 *Nature Communications* 2020; **11**(1): 2251.
- 802 55. den Hartog G, Schepp RM, Kuijper M, et al. SARS-CoV-2–Specific Antibody Detection for  
803 Seroepidemiology: A Multiplex Analysis Approach Accounting for Accurate Seroprevalence. *The*  
804 *Journal of Infectious Diseases* 2020; **222**(9): 1452-61.
- 805 56. Bates D, Mächler M, Bolker B, Walker S. Fitting linear mixed-effects models using lme4. *arXiv*  
806 *preprint arXiv:14065823* 2014.
- 807 57. Kuznetsova A, Brockhoff PB, Christensen RH. lmerTest package: tests in linear mixed effects  
808 models. *Journal of statistical software* 2017; **82**(13): 1-26.
- 809 58. Therneau TM, Grambsch PM. The Cox model. Modeling survival data: extending the Cox  
810 model: Springer; 2000: 39-77.
- 811 59. Benjamini Y, Hochberg Y. Controlling the False Discovery Rate: A Practical and Powerful  
812 Approach to Multiple Testing. *Journal of the Royal Statistical Society Series B (Methodological)* 1995;  
813 **57**(1): 289-300.
- 814 60. Aantal in het ziekenhuis opgenomen patiënten naar datum van ziekenhuisopname. 2020.  
815 <https://www.rivm.nl/coronavirus-covid-19/grafieken> (accessed 19 January 2021).
- 816 61. Maart 2020: Maatregelen tegen verspreiding coronavirus, intelligente lockdown. 2020.  
817 [https://www.rijksoverheid.nl/onderwerpen/coronavirus-tijdlijn/maart-2020-maatregelen-tegen-](https://www.rijksoverheid.nl/onderwerpen/coronavirus-tijdlijn/maart-2020-maatregelen-tegen-verspreiding-coronavirus)  
818 [verspreiding-coronavirus](https://www.rijksoverheid.nl/onderwerpen/coronavirus-tijdlijn/maart-2020-maatregelen-tegen-verspreiding-coronavirus) (accessed 19 January 2021).


819

Figure 1




**Figure 1. Flow diagram and study procedures.** **a**) Flow diagram describing the recruitment of households, sample sizes, and study outcomes. We initially contacted 97 index cases that were tested positive for SARS-CoV-2. After exclusion of cases that did not meet the inclusion criteria or did not consent, 50 index cases and their household contacts (N=137) were recruited. Mucosal lining fluid (MLF) antibodies were analysed as a primary outcome in both indexes and household contacts. Secondary analyses (correlation of MLF antibodies with viral load and symptoms, serology, estimation of SARS-CoV-2 exposure) were performed. **b**) Study timeline, with respect to the number of hospitalizations due to COVID-19 over time and COVID-19 control measures in the Netherlands<sup>60,61</sup>. The first home visit was conducted at the peak of hospitalizations at March 26, and the last visit was one day after the reopening of primary schools, at May 13. **c**) Overview of the study design and measurements. Home visits were initiated after the index was tested positive for SARS-CoV-2 by PCR, to collect naso- and oropharyngeal swabs for viral load determination as well as nasal MLF samples. Subsequent MLF samples were collected and stored by the participants, who also completed a daily symptom survey. At the end of the study, blood samples were collected for serological analyses.

Figure 2




**Figure 2. Serum antibody responses against SARS-CoV-2 in COVID-19 patients and household contacts. a)** Seroconversion heatmap for index cases (N=50) and contacts (N=129) for each antigen and antibody isotype measurement, as well as seroconversion rate for any single antibody measurement (anySero). Seroconversion threshold was calculated as the mean of the controls plus 2\*standard deviation. **b)** Serum antibody responses against SARS-CoV-2 in COVID-19 in index cases correlated with mucosal antibody responses. IgM, IgG, and IgA antibody responses against SARS-CoV-2 spike protein (S), receptor binding domain (RBD) and nucleocapsid (N) were measured in sera or in mucosal lining fluid at the end of the study. Antibody levels are expressed as a ratio compared to the mean of pre-corona samples (relative ratio). Data are shown for index cases (N=50). Spearman correlations were calculated and p-values are reported directly in the figure.

Figure 3




**Figure 3. Mucosal antibody responses during SARS-CoV-2 infection in index cases (N=49).** **a)** IgM, IgG and IgA antibody responses against SARS-CoV-2 spike (S), receptor binding domain (RBD) or nucleocapsid (N) collected in mucosal lining fluid at d0 were correlated with days since symptom onset (PSO) and viral load. Spearman correlations were calculated, \*  $p < 0.05$ , \*\*  $p < 0.01$ , \*\*\*  $p < 0.001$ . p-values of borderline significant tests are reported directly in the figure. **b)** Longitudinal mucosal antibody responses to S, RBD and N, plotted relative to the days PSO. Pre-SARS-CoV-2 controls are presented in the grey boxplots for comparison ( $n=17$ ). Values within each timeframe were compared with the controls with the Wilcoxon-signed rank test. A non-parametric Loess curve is shown as red line to visualize the trend over time. Measurements from the same individual are connected with a grey line. **c)** Antibody measurements within the depicted timeframes were correlated with each other. Spearman correlation coefficient is presented.

Figure 4




**Figure 4. Influence of age and mucosal antibody levels on the progression of systemic and respiratory COVID-19 symptoms.** **a)** The number of respiratory (RS) and systemic disease (SDS) symptoms were recorded for index cases (N = 49) for each day during the 28 day study period. Data are plotted relative to the time of symptom onset and values were binned into 3-day time frames. A non-parametric loess curve is shown as a red (SDS) or blue (RS) line in order to visualize the trend over time. **b)** A linear mixed-effect model (MEM) was fit to the data per symptom group. The response was specified as the number of symptoms on a given day, and explanatory fixed effects variables were: day since symptom onset, age, and sex. Time since symptom onset was also specified as a random slope, and Sample ID as a random intercept. A significant effect of age ( $p = 0.0165$ ) was demonstrated for RS. Predicted symptom values from the model are plotted against index case age with 95% confidence interval bands. **c)** Longitudinal mucosal antibody measurements were added as fixed effect variables in a univariate fashion to the MEM from (b). The predicted change in symptoms per unit increase of antibody signal is presented with 95% confidence intervals, and p-values for the association are plotted on the right (\*  $p < 0.05$ ; \*\*  $p < 0.01$ ; \*\*\*  $p < 0.001$ ).

Figure 5



**Figure 5 Identification of household contact cases and assessment of their mucosal SARS-CoV-2 antibody responses. a)** Contact cases were classified into case or non-case first by their PCR result on enrolment, followed by seroconversion for either IgM, IgG or IgA against the S-protein, and mucosal antibody levels for either IgM, IgG or IgA against the S-protein at the end of the follow-up. The PCR positive threshold was set at a Ct value <36. The seroconversion threshold was based on the mean + 2\*SD of the log<sub>2</sub>-transformed pre-SARS-CoV-2 control samples. To identify cases based on mucosal antibodies against S, we used a naive Bayes model that was trained by the mucosal antibody measurements of the positive study participants (cases) and the pre-SARS-CoV-2 control samples (controls). **b)** Contacts were classified by their household as either the primary (N=9) or a non-primary (N=58) case, based on time of symptom onset. Mucosal antibody responses of the primary household contact cases collected at d0 were correlated with viral load. Spearman correlations were calculated, \* p < 0.05, \*\* p < 0.01, \*\*\* p < 0.001. p-values of borderline significant tests are reported directly in the figure. **c)** IgM, IgG and IgA antibody responses against Spike protein (S), receptor binding domain (RBD) and nucleocapsid (N), measured in mucosal lining fluid. Data are plotted relative to the time of symptom onset of the index case in the respective household, and pre-SARS-CoV-2 control samples are presented for comparison. A non-parametric loess curve is shown as a red (primary cases) and a blue (non-primary cases) line to visualize the trend over time.

Figure 6



**Figure 6. SARS-CoV-2 infection, viral load and number of symptoms of contact cases, split into four age groups. a)** Proportion of infected household contacts per age group. Sixteen out of 33 primary school-age children (1-12y) were infected (48%), 13 out of 23 children aged 13-18y (56%), 27 out of 50 adults aged 19-49 years (54%) and 19 out of 31 contacts older than 50 years (61%). **b)** Proportion of asymptomatic disease among household cases (N=75) at study enrolment within each age category. Seven of the children below 12 years were asymptomatic (44%), two of the children up to 18 years (15%), seven of the adults up to 49 years (28%) and two of the contacts older than 50 years (11%). **c)** The correlation between the total number of reported symptoms and the age of the infected household contacts. Pearson’s correlation and significance is depicted in the figure. The shape of the datapoints represents the method by which a contact was classified as a case and the color of the datapoints shows the viral load at study start.